Phase Ⅱ Study of Combined Sintilimab and Anlotinib with Gemcitabine plus Cisplatin in Advanced Biliary Tract Cancer: Efficacy, Safety and Optimize Dose
Jingjing Li(Shenyang Ligong University), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Weijing Sun(University of Kansas Medical Center), Qing Wei(Shanghai Tenth People's Hospital), Shurui Zhou(Zhejiang Cancer Hospital), Junrong Yan, Bingchen Wu(Hangzhou Hospital of Traditional Chinese Medicine), Yuhua Zhang(Zhejiang Cancer Hospital), Zhe Han(University of Maryland, Baltimore), Da Li(Sir Run Run Shaw Hospital), Wei Wu(Tianjin University), Yiwen Zhou(Weihai Maternal and Child Health Hospital), Qi Xu(Zhejiang Cancer Hospital), Cong Luo(Central South University), Qinhong Zheng(Quzhou City People's Hospital), Xing Sun, xinbao wang(Zhejiang Cancer Hospital), Yang Shao(Sanya University), Fabiao Zhang(Wenzhou Medical University), Xiaoqing Xu(Zhejiang Chinese Medical University)
Cited by 1
Related Papers
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
|癌症：英文版|2023|412
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
|JAMA|2023|384
ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption
|Journal of Clinical Investigation|2013|341